论文部分内容阅读
目的探讨可溶性成纤维细胞活化蛋白(sFAP)在肺癌患者外周血中的表达及其临床意义。方法抽取74例肺癌患者和74例健康人群的外周血,采用ELISA法检测sFAP的表达,电化学发光免疫分析法检测肿瘤标志物,并绘制ROC曲线,分析sFAP与临床特征及肿瘤标志物的相关性。结果 sFAP在肺癌患者外周血中的表达高于健康人群(P<0.01)。肺癌患者sFAP的高表达与淋巴结转移有关(P<0.05),未发现与患者性别、年龄、病理类型、肿瘤分期、远处转移有关(P>0.05)。以sFAP为1.07ng/ml作为最佳诊断界值时,检测肺癌的灵敏度为85.1%,特异度为86.3%;以联合干预因子为0.99作为最佳诊断界值时,sFAP联合肿瘤标志物检测肺癌的灵敏度为94.6%,特异度为89.2%。结论 sFAP在肺癌患者外周血中高表达,且与肺癌的淋巴结转移密切相关;动态监测sFAP可预测肺癌的疗效和预后。
Objective To investigate the expression of soluble fibroblast activating protein (sFAP) in peripheral blood of patients with lung cancer and its clinical significance. Methods Totally 74 patients with lung cancer and 74 healthy people were enrolled in this study. The expression of sFAP was detected by ELISA. The tumor markers were detected by electrochemiluminescence immunoassay. The ROC curve was drawn. The correlation between sFAP and clinical features and tumor markers Sex. Results The expression of sFAP in peripheral blood of patients with lung cancer was higher than that of healthy people (P <0.01). The high expression of sFAP in lung cancer patients was associated with lymph node metastasis (P <0.05), and no correlation was found with the gender, age, pathological type, tumor stage and distant metastasis (P> 0.05). When sFAP was 1.07ng / ml, the sensitivity of detection of lung cancer was 85.1% and the specificity was 86.3%. When the joint intervention factor was 0.99 as the best diagnostic value, sFAP combined with tumor markers in detecting lung cancer The sensitivity was 94.6% and the specificity was 89.2%. Conclusion sFAP is highly expressed in peripheral blood of patients with lung cancer and is closely related to lymph node metastasis of lung cancer. Dynamic monitoring of sFAP can predict the efficacy and prognosis of lung cancer.